OS THERAPIES INCORPORATED Noncash or Part Noncash Acquisition, Payables Assumed
OS THERAPIES INCORPORATED (OSTX) reported Noncash or Part Noncash Acquisition, Payables Assumed of $31.25 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionPayablesAssumed1 · last filed 2026-03-31
- OS THERAPIES INCORPORATED noncash or part noncash acquisition, payables assumed for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- OS THERAPIES INCORPORATED noncash or part noncash acquisition, payables assumed for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- OS THERAPIES INCORPORATED noncash or part noncash acquisition, payables assumed for the quarter ending 2024-06-30 was $0.00.
- OS THERAPIES INCORPORATED noncash or part noncash acquisition, payables assumed for the quarter ending 2024-03-31 was $31.25K.
- OS THERAPIES INCORPORATED noncash or part noncash acquisition, payables assumed for fiscal 2024 was $31.25K, a 75.00% decline from fiscal 2023.
- OS THERAPIES INCORPORATED noncash or part noncash acquisition, payables assumed for fiscal 2023 was $125.00K.
| Period end | Noncash or Part Noncash Acquisition, Payables Assumed 3 month | Noncash or Part Noncash Acquisition, Payables Assumed 6 month | Noncash or Part Noncash Acquisition, Payables Assumed 9 month | Noncash or Part Noncash Acquisition, Payables Assumed 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $0.00 derived: sum of 2 quarters · filed 2026-03-31 | $0.00 derived: sum of 3 quarters · filed 2026-03-31 | $31.25K 10-K · filed 2026-03-31 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $31.25K 10-Q · filed 2025-11-14 | $62.50K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | $31.25K 10-Q · filed 2025-08-18 | $62.50K derived: sum of 3 quarters · filed 2025-08-18 | $93.75K derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | $31.25K 10-Q · filed 2025-05-15 | $62.50K derived: sum of 2 quarters · filed 2025-05-15 | $93.75K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $31.25K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $62.50K derived: sum of 2 quarters · filed 2025-03-31 | $125.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | $31.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-15 | $93.75K 10-Q · filed 2024-11-15 | ||
| 2023-06-30 | $62.50K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |